- Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
- Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinier S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
- Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.029. Epub ahead of print.
•• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 10.)
- EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
- Schmidt MK, Kelly JE, Brédart A, Cameron DA, de Boniface J, Easton DF, Offersen BV, Poulakaki F, Rubio IT, Sardanelli F, Schmutzler R, Spanic T, Weigelt B, Rutgers EJT.
- Eur J Cancer. 2023 Jan 10. doi: 10.1016/j.ejca.2022.11.036. Epub ahead of print.
- Review, Guideline
- Free Full Text
- Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
- Flaherty C, Dorff TB.
- OncLive. 2023 Jan 10.
- Conference news
- Free Full Text
- Polygenic risk scores and breast cancer risk prediction.
- Roberts E, Howell S, Evans G.
- Breast. 2022 Jan 9:S0960-9776(23)00003-6. doi: 10.1016/j.breast.2023.01.003. Epub ahead of print.
- Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
- Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez E, Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli G, Goldgar DE, Palmer JR, Domchek SM, Weitzel JN, Nathanson KL, Kraft P, Couch FJ.
- J Clin Oncol. 2023 Jan 9:JCO2201239. doi: 10.1200/JCO.22.01239. Epub ahead of print.
- PMID: 36623243
- PubMed abstract
- Targeting the DNA damage response for cancer therapy.
- Curtin NJ.
- Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.
- PMID: 36606678
- PubMed abstract
- Review
- Free Full Text
- Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
- Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
- Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.
- PMID: 36604691
- PubMed abstract
- Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up.
- Webster AJ, Shanno JN, Santa Cruz HS, Kelly BN, Garstka M, Henriquez A, Specht MC, Gadd MA, Verdial FC, Nguyen A, Oseni TO, Coopey SB, Smith BL.
- Ann Surg Oncol. 2023 Jan 5. doi: 10.1245/s10434-022-13006-w. Epub ahead of print.
- PMID: 36604360
- PubMed abstract
- Source abstract
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.
- Granata V, Fusco R, Setola SV, Galdiero R, Maggialetti N, Silvestro L, De Bellis M, Di Girolamo E, Grazzini G, Chiti G, Brunese MC, Belli A, Patrone R, Palaia R, Avallone A, Petrillo A, Izzo F.
- Cancers (Basel). 2023 Jan 5;15(2):351. doi: 10.3390/cancers15020351.
- Review
- Free Full Text
- Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
- Penn CA, Alvarez RD.
- JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.
- PMID: 36603168
- PubMed abstract
- Review
- Free Full Text
- A polygenic two-hit hypothesis for prostate cancer.
- Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, Jung CH, Yamaguchi TN, Heisler LE, Jovelin R, Costello AJ, Pope BJ, Kishan AU, Corcoran NM, Bristow RG, Waszak SM, Weischenfeldt J, He HH, Hung RJ, Hovens CM, Boutros PC.
- J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093/jnci/djad001. Epub ahead of print.
- PMID: 36610996
- PubMed abstract
- Source abstract
- Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
- Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM.
- Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. Epub ahead of print.
- PMID: 36609003
- PubMed abstract
- Source abstract
- Review
- Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
- Qi F, Xu Z, Zou Q.
- Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
- PMID: 36604272
- PubMed abstract
- Source abstract
- Letter
•• Original research:
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
- PMID: 36243543
- PubMed abstract
- Source abstract
•• Reply:
Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
- PMID: 36623951
- PubMed abstract
- Source abstract
- Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants.
- Subaşıoğlu A, Güç ZG, Gür EÖ, Tekindal MA, Atahan MK.
- Eur J Breast Health. 2023 Jan 1;19(1):55-69. doi: 10.4274/ejbh.galenos.2022.2022-7-2.
- PMID: 36605468
- PubMed abstract
- Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
- Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
- Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26.
- PMID: 36599598
- PubMed abstract
- Source abstract
- Review
- Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
- Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
- IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.
- PMID: 36605692
- PubMed abstract
- Source abstract
- Case report
- Free PMC article
- Free Full Text
•• Letter:
Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".
- PMID: 36605686
- PubMed abstract
- Free Full Text
- Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
- Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
- J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
- PMID: 36603850
- PubMed abstract
- Source abstract
- Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
- Brook MN, Ní Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA.
- Eur Urol. 2022 Dec 15:S0302-2838(22)02838-X. doi: 10.1016/j.eururo.2022.11.019. Epub ahead of print.
- PMID: 36528478
- PubMed abstract